GlassScriptPhysician profile
Rangaswamy Chintapatla
NPI 1003131640
$49,824.84
in general payments reported to CMS, 2019-2025
25 companies · $4,505 in 2025
The $4,505 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,960 · 2020: $4,355 · 2021: $6,650 · 2022: $18K · 2023: $6,991 · 2024: $1,769 · 2025: $4,505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $10K · Travel and Lodging: $2,567 · Food and Beverage: $383 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,201.50 |
| Travel and Lodging | $2,567.44 |
| Food and Beverage | $382.61 |
| Education | $114.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $11,317.84 | 2019-2023 | Venclexta |
| Astrazeneca Pharmaceuticals LP | $9,517.07 | 2019-2022 | |
| Kite Pharma, INC. | $5,258.04 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $5,153.61 | 2019-2025 | Opdivo |
| Janssen Biotech, INC. | $3,588.16 | 2019 | |
| Celgene Corporation | $3,420.69 | 2020-2025 | Reblozyl |
| Glaxosmithkline, LLC. | $2,532.00 | 2021-2023 | Ojjaara |
| Array Biopharma INC | $2,400.00 | 2021 | |
| Pfizer INC. | $1,854.85 | 2019-2024 | |
| Morphosys, US INC. | $1,455.00 | 2022 | |
| Daiichi Sankyo INC. | $1,410.00 | 2023 | |
| Incyte Corporation | $1,100.00 | 2025 | |
| Beigene, LTD. | $450.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $171.15 | 2019 | |
| Merck Sharp & Dohme LLC | $54.84 | 2019-2024 | Keytruda |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $34.35 | 2019 | |
| Novocure INC. | $30.79 | 2019 | |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Emd Serono, INC. | $16.83 | 2019 | |
| Seagen INC. | $13.67 | 2020 | |
| Pharmacosmos Therapeutics INC. | $13.03 | 2021 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rangaswamy Chintapatla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.